Year 2013 / Volume 105 / Number 6
Puntos De Vista
Linaclotide in the treatment of patients with irritable bowel syndrome and constipation - analysis of an opportunity

345-354

Fernando Carballo. Comisión de Excelencia Clínica de la Sociedad Española de Patología Digestiva (SEPD). Servicio de Medicina de Aparato Digestivo. Unidad de Gestión Clínica de Digestivo. Hospital Clínico Universitario Virgen de la Arrixaca de Murcia. Instituto Murciano de Investigación Biosanitaria (IMIB)

Abstract
Linaclotide is a secretagogue that provides a combined effect on visceral pain. The European Medicines Agency has authorized its indication for the symptomatic treatment of moderate to severe irritable bowel syndrome with constipation in adults. The purpose of this review is to discuss the clinical framework for linaclotide use in our setting, the drug’s characteristics and pre-clinical development, and the clinical studies supporting its use in order to establish relevant views regarding its validity and clinical applicability. The results suggest that the only —non- severe— adverse effect associated with this drug is diarrhea. As regards effectiveness, linaclotide consistently shows favorable, significant differences in absolute risk versus placebo for all objective outcome variables described by regulatory agencies, with a combined pain and constipation response between 12.6% and 22.8% according to the variable and trial under consideration. This response is sustained and drug-related, as it goes away upon discontinuation. To conclude, linaclotide has a safety and efficacy profile that, from a clinical perspective, warrants its use for patients meeting irritable bowel syndrome and constipation criteria, with significant symptoms that cannot be relieved with other less specific measures. In the absence of predictive rules for response, it is recommended that, should the patient fail to respond, he or she should be considered not eligible for linaclotide therapy, and both indication and treatment continuity should be reserved for objective responders alone.
Share Button
New comment
Comments
No comments for this article
Related articles
Citation tools
Fernando Carballo. Comisión de Excelencia Clínica de la Sociedad Española de Patología Digestiva (SEPD). Servicio de Medicina de Aparato Digestivo. Unidad de Gestión Clínica de Digestivo. Hospital Clínico Universitario Virgen de la Arrixaca de Murcia. Instituto Murciano de Investigación Biosanitaria (IMIB). Linaclotide in the treatment of patients with irritable bowel syndrome and constipation - analysis of an opportunity. 345-354


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 34 visits.
This article has been downloaded 34 times.
Share
This article has been rated by 1 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology